Indicated for treatment of manic episodes associated with bipolar disorderDepakote initial dose: 750 mg/day PO in divided dosesDepakote ER initial dose: 25 mg/kg PO once daily Increase as rapidly as possible to achieve the lowest therapeutic dose that provides desired clinical effect or plasma concentrationComplex partial seizures: Indicated as monotherapy and adjunctive therapy for complex partial seizures that occur either in isolation or in association with other types of seizuresSimple and complex absence seizures: Also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures10-15 mg/kg/day PO initially; may increase by 5-10 mg/kg/week to achieve optimal clinical response; not to exceed 60 mg/kg/dayDepakote: If daily dose >250 mg, give as divided doseIndicated for prophylaxis of migraine headaches; there is no evidence of use for acute treatmentDepakote ER initial dose: 500 mg PO qDay for 1 weekConversion to monotherapy: Decrease concomitant antiepilepsy drug dosage ~25% q2weeksConversion from Depakote to Depakote ER: Administered Depakote ER once daily using a dose 8-20% higher than the total daily dose of DepakoteCapsules may be opened and sprinkled on spoonful of soft food immediately before administrationDepakote or Depakote Sprinkles: If daily dose >250 mg, give as divided doseComplex partial seizures: Indicated as monotherapy and adjunctive therapy for complex partial seizures that occur either in isolation or in association with other types of seizuresSimple and complex absence seizures: Also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures10-15 mg/kg/day PO initially; may increase by 5-10 mg/kg/week to achieve optimal clinical response; not to exceed 60 mg/kg/dayConversion to monotherapy: Decrease concomitant antiepilepsy drug dosage ~25% q2weeksConversion from Depakote to Depakote ER: Administered Depakote ER once daily using a dose 8-20% higher than the total daily dose of DepakoteCapsules may be opened and sprinkled on spoonful of soft food immediately before administrationDepakote or Depakote Sprinkles: If daily dose >250 mg, give as divided doseCerebral pseudoatrophy (acute or subacute cognitive decline and behavioral changes (apathy or irritability)Aspermia, azoospermia, decreased sperm count, decreased spermatozoa motility, male infertility, and abnormal spermatozoa morphologyMitochondrial disorders caused by mutations in mitochondrial DNA polymerase-gamma (POLG; eg, Alpers-Huttenlocher Syndrome) and children <2 years of age who are suspected of having a POLG-related disorderMigraine headache prevention in women who are pregnant or plan to become pregnantProbability of thrombocytopenia increases significantly at total trough valproate plasma concentrations exceed 110 mcg/mL in females and 135 mcg/mL in malesHepatotoxic (age <2 years, higher risk of fatal hepatotoxicity); see Black Box WarningsPOLG mutations; see Contraindications and Black Box WarningsDiscontinue if hyperammonemia/encephalopathy occurs; check ammonia level if emesis occurs or if the patient displays lethargy or abnormal behavior; evaluate patient for urea cycle disorder (see Contraindications) or hepatotoxicity (see Black Box Warnings);Pancreatitis, including fatalities reported (see Black Box Warnings)Hypothermia has been reported during valproate therapy with or without associated hyperammonemia; this adverse reaction can also occur in patients using concomitant topiramateIn utero exposure increases risk for poor cognitive outcomes and anatomical malformations, compared with 3 other common AEDs (carbamazepine, lamotrigine, phenytoin); see Black Box WarningsPotential for thrombocytopenia, porphyria, and multiorgan hypersensitivity reaction (also known as drug reaction with eosinophilia and systemic symptoms or DRESS)May produce false-positive urine ketone test and alter TFTsReversible cerebral and cerebellar atrophy reported; monitor motor and cognitive function routinely and assess for signs and symptoms of brain atrophyMay cause CNS depression and impair physical or mental abilitiesSomnolence in the elderly can occur; divalproex dosage should be increased slowly and with regular monitoring for fluid and nutritional intakeNot for administration to post-traumatic seizure prophylaxis in patients with acute head trauma (increased mortality reported when used)A pregnancy exposure registry monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), during pregnancy; encourage women on therapy during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling toll-free 1-888-233-2334 or visiting the website, http://www.aedpregnancyregistry.org/.

You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.Conversely, the presence of this link does not imply the linked site’s endorsement of Depakote.com or AbbVie.You are about to enter a site that is for U.S. Healthcare Professionals only. This means it is active against both partial-onset and generalized-onset seizures. Here in the USA, drug is used for epilepsy and migraine control. Valproic acid is available in many different forms.